stoneroad and all - this is most likely a step in the commercialization process that is necessary and time-dependent.
Hard to tell whether they are registering for 3 different uses, three different products, or a single product/use and multiple options.
Prior to filing with the FDA and requesting approval, any generic compound (i.e. Bavituximab) needs to have an approved Brand Name equivalent under which the company can sell it's product.
Typically, several names will be held (registered) while market research is performed (i.e. don't call Chevy model NOVA in a Latin American country - it means 'Doesn't Move' and won't sell as a car) and a formal submittal is placed for review/approval.
This is a good sign and a required step before approval. No product can get approved prior to having an appropriate, reviewed and formally accepted Brand Name.
It's likely Peregrine is evaluating 3 options for the same product, and will end up with one, although it is not possible to ascertain that at this moment. Also, while one can figure out some info with the generic name (possible Latin roots, compound segments with a therapeutic meaning, etc.), Brand Names usually mean nothing... Other than needing to be sufficiently unique, non offensive, easy to remember/pronounce, generate marketing value through intrigue, etc.
The more of these they register, the better the signals. This is a required step in commercialization, and one that has a life span (i.e. can't get it too early and not use it - it expires without timely use).
And the SP sucks today which is bringing all kinds of dark thoughts to everyone's mind. This thing is blowing in the wind right now for lack of driving forces. They will come in due time.
Best,
MH
News 
Market Data 
Discover 
